There are currently 70 active clinical trials seeking participants for Cystic Fibrosis research studies. The states with the highest number of trials for Cystic Fibrosis participants are Ohio, California, New York and Florida.
Regional Phenotyping of CF and Non-CF Bronchiectasis
NCT04793867
Recruiting
The Investigators propose to study pediatric subjects who are diagnosed with cystic fibrosis (CF) and patients with non-CF bronchiectasis, with the goal of developing markers of CF lung disease severity, progression, and therapy response. The Investigator's central hypothesis is that image-based markers can forecast pathophysiology prior to spirometric changes.
Gender:
ALL
Ages:
Between 5 years and 100 years
Trial Updated:
02/18/2025
Locations: Penny New, Cincinnati, Ohio
Conditions: Cystic Fibrosis, Non-CF Bronchiectasis
Register for Updates
Hormonal Responses to a Mixed Meal in People with Cystic Fibrosis
NCT06163482
Recruiting
In this exploratory study, the hormonal responses to a mixed meal will be examined in people with cystic fibrosis. The aim of this study is to find correlates with impaired glucose tolerance that is associated with this population.
Gender:
ALL
Ages:
Between 18 years and 45 years
Trial Updated:
01/08/2025
Locations: University of Cincinnati, Cincinnati, Ohio
Conditions: Cystic Fibrosis
Register for Updates
Testing Drug Efficacy in Cystic Fibrosis Through N-of-1 Trials
NCT04580368
Recruiting
The purpose of this study is to validate and utilize a personalized medicine approach to identify potential treatments with current FDA approved CFTR modifiers for non-approved CF gene mutations. The study will perform ex vivo testing of CFTR function and current marketed CFTR modulating drugs on expanded nasal cells at Cincinnati Children's Human Nasal Epithelium (HNE) Core Laboratory. The results will be confirmed and translated into bedside care through an N of 1 trial to determine effectiven... Read More
Gender:
ALL
Ages:
6 years and above
Trial Updated:
09/18/2024
Locations: CCHMC, Cincinnati, Ohio
Conditions: Cystic Fibrosis
Register for Updates
Regional Monitoring of CF Lung Disease
NCT06339593
Recruiting
The main reason for this research study is to learn more about some new tests that are being developing for patients with Cystic Fibrosis (CF) to measure changes in the lungs. In this study, the focus will be to learn how stopping Airway Clearance (ACT) and re-starting ACT can affect these tests. These new tests include using a breathable gas called Xenon (Xe) with MRI (magnetic resonance imaging) to improve the pictures of changes in the lungs. The Xenon (Xe) gas that has been treated to have a... Read More
Gender:
All
Ages:
Between 12 years and 21 years
Trial Updated:
03/29/2024
Locations: Cincinnati Children's Hospital, Cincinnati, Ohio
Conditions: Cystic Fibrosis
Register for Updates
A Research Study to Advance the CF Therapeutics Pipeline for People Without Modulators
NCT06504589
Recruiting
The REACH study is for people with CF who do not take cystic fibrosis transmembrane conductance regulator (CFTR) modulators. The goal of the REACH study is to collect research data, including health data and specimens, from people with CF who do not take CFTR modulators. This data may be used to inform CF research, help design CF clinical trials and support the development of new treatments for people with CF who do not take CFTR modulators. Another goal of this study is to learn about research... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
03/24/2025
Locations: The Children's Hospital Alabama, University of Alabama at Birmingham, Birmingham, Alabama +67 locations
Conditions: Cystic Fibrosis
Register for Updates
Health Outcomes of Parents With Cystic Fibrosis-Aim 2
NCT06296394
Recruiting
The goal of this observational prospective study is to determine the health impact of parenthood on United States (US) people with CF in the era of CF transmembrane regulator protein (CFTR) modulators. The investigators will collect physical and mental health data to comprehensively evaluate the impact of parenthood in CF with widespread highly effective CFTR modulator use. The main hypotheses this study aims to examine are: H1: Parents with CF and moderate-to-severe depression have more rapid... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/24/2025
Locations: University of Alabama-Birmingham, Birmingham, Alabama +17 locations
Conditions: Cystic Fibrosis, Parenthood Status
Register for Updates
Streamlined Treatment of Pulmonary Exacerbations in Pediatrics
NCT06654752
Recruiting
The STOP PEDS RCT is a multicenter, parallel, open label randomized controlled trial evaluating the long-term (one year) and short-term safety and efficacy of two antibiotic treatment strategies for the management of outpatient pulmonary exacerbations (PEx) in the pediatric CF population.
Gender:
ALL
Ages:
Between 3 years and 18 years
Trial Updated:
03/24/2025
Locations: The Children's Hospital Alabama & University of Alabama at Birmingham, Birmingham, Alabama +32 locations
Conditions: Cystic Fibrosis
Register for Updates
Natural History of Noncirrhotic Portal Hypertension
NCT02417740
Recruiting
Background: - Noncirrhotic Portal Hypertension (NCPH) is caused by liver diseases that increase pressure in the blood vessels of the liver. It seems to start slowly and not have many warning signs. Many people may not even know that they have a liver disease. There are no specific treatments for NCPH. Objectives: - To learn more about how NCPH develops over time. Eligibility: - People age 12 and older who have NCPH or are at risk for getting it. In the past year, they cannot have had other... Read More
Gender:
ALL
Ages:
Between 12 years and 100 years
Trial Updated:
03/21/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Cystic Fibrosis, Immunologic Deficiency Syndrome, Turner Syndrome, Congenital Hepatic Fibrosis, Idiopathic Non-Cirrhotic Portal Hypertension
Register for Updates
High Resolution Micro OCT Imaging
NCT03256773
Recruiting
The purpose of this study is to learn about using the imaging to make images of the lungs and nose with the long-term goal of the research leading to potential treatments and new therapies for patients with cystic fibrosis.
Gender:
ALL
Ages:
14 years and above
Trial Updated:
03/21/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Cystic Fibrosis, COPD, PCD - Primary Ciliary Dyskinesia, Covid19, Sinusitis
Register for Updates
A Phase 1/2 Study of VX-522 in Participants With Cystic Fibrosis (CF)
NCT05668741
Recruiting
The purpose of this study is to evaluate the safety, and tolerability and efficacy of VX-522 in participants 18 years of age and older with cystic fibrosis and a cystic fibrosis transmembrane conductance regulator (CFTR) genotype not responsive to CFTR modulator therapy.
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
03/18/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama +40 locations
Conditions: Cystic Fibrosis
Register for Updates
Evaluation of VX-121/Tezacaftor/Deutivacaftor in Cystic Fibrosis (CF) Participants 1 Through 11 Years of Age
NCT05422222
Recruiting
The purpose of this study is to evaluate the pharmacokinetics, safety, tolerability and efficacy of VX-121/tezacaftor/deutivacaftor (VX-121/TEZ/D-IVA) in CF participants with at least 1 triple combination responsive (TCR) mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
Gender:
ALL
Ages:
Between 1 year and 11 years
Trial Updated:
03/18/2025
Locations: Children's Hospital of Orange County, Orange, California +33 locations
Conditions: Cystic Fibrosis
Register for Updates
GLP-1 Agonist Therapy in Cystic Fibrosis-Related Glucose Intolerance
NCT04731272
Recruiting
Diabetes is a major co-morbidity in pancreatic insufficient cystic fibrosis (PI-CF) and associated with worse outcomes. While reduced β-cell mass contributes to the insulin secretory defects that characterizes cystic fibrosis-related diabetes (CFRD), other modifiable determinants appear operative in the emergence and progression of abnormal glucose tolerance towards diabetes. Identifying interventions to preserve β-cell function are crucial for delaying and potentially preventing CFRD developmen... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/12/2025
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Cystic Fibrosis, Pancreatic Insufficiency, Abnormal Glucose Tolerance, Diabetes
Register for Updates